Renal function outcomes in patients with muscle‐invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE‐01 study
- 15 March 2021
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 149 (1) , 186-190
Abstract
The use of pembrolizumab has been largely accepted in several advanced types of cancers. PURE 01 study (NCT02736266) enrolled consecutively 143 patients with muscle‐invasive bladder cancer who received 3 cycles of pembrolizumab 200 mg every 3 weeks before planned radical cystectomy (RC). Clinical, pathological and laboratory data were collected to investigate the relationship between renal function, immunotherapy and cancer‐related outcomes. Serum creatinine and estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI) creatinine‐equation 2009 were reported at baseline and after every cycle of pembrolizumab; the T stage from clinical classification TNM (cTNM) was stated before the treatment. Our analysis did not demonstrate a significant impairment of eGFR after any cycle of pembrolizumab, neither in the overall cohort nor in subgroups considering the T stages or the CKD G‐categories according to K‐DIGO 2012 classification. In conclusion, in neoadjuvant setting before RC our results suggest that pembrolizumab administration is safe for renal function preservation.Keywords
This publication has 16 references indexed in Scilit:
- Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literatureCritical Reviews in Oncology/Hematology, 2021
- Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆Annals of Oncology, 2020
- Interstitial nephritis with pembrolizumab: A case report and reviewJournal of Oncology Pharmacy Practice, 2020
- Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder CancerEuropean Urology, 2020
- Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 TrialEuropean Urology, 2020
- Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 StudyEuropean Urology, 2020
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant HistologiesEuropean Urology, 2020
- Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter StudyJournal of the American Society of Nephrology, 2020
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II StudyJournal of Clinical Oncology, 2018
- Chapter 1: Definition and classification of CKDKidney International Supplements, 2013